Given the mechanism that ACTL6A activated the MYC/ CDK2 axis, we hypothesized that a CDK2 inhibitor would have potentially therapeutic effects against TNBC in combination with the first-line chemotherapy drug of breast cancer, paclitaxel (PTX). This evidence concerns the gene ACTL6A and breast carcinoma.